ClinicalTrials.gg
CompletedNCT02094599Updated May 13, 2014

A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users

A Phase 1 interventional study of Dronabinol 10 mg and Dronabinol 30 mg in Drug Abuse, Medication, sponsored by INSYS Therapeutics Inc. Completed at 1 site in Canada. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2014-05-13.

Sponsored by INSYS Therapeutics Inc · Phase 1 and Interventional

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
43
Allocation
Not applicable
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 81 studies in Substance-Related Disorders with a site in Canada — 26 open to participants now, 29 under way, none of them phase 3. Substance-Related Disorders · Canada.

Enrollment
48th of 71
43 · median 74
Started
2014
with 6 others
Phase 1
7 of 81
none open now
Registered
14th of 81
by date

Among the 81 studies in Substance-Related Disorders with a site in Canada, this one is the 48th largest by enrollment of the 71 interventional ones that give a count, is one of 7 that started in 2014, is one of 7 in phase 1, and was the 14th registered.

Substance-Related Disorders

2,241 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.

Browse Substance-Related Disorders studies →

Open to participants now

26 of the 81 studies in Substance-Related Disorders with a site in Canada are open now. Recruiting first, the newest first:

21 more — sign in →

All 26 open studies →

A study can be open while its sites in Canada have not opened yet or have stopped. Only those recruiting at a site in Canada →

Who these studies take

Of the 264 Substance-Related Disorders studies recruiting now, 129 (49%) set no upper age limit and 117 (44%) stop at 75 or younger; 55 take children under 18; 89 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Substance-Related Disorders with a site in Canada, or all of them as a file.
02

Study summary

The primary objective of this study is to evaluate the abuse potential of dronabinol oral solution in recreational cannabinoid users.

Read the detailed description

Following a four-day period for screening and qualification, there are five treatment visits with a minimum 8-day washout between treatments. Each participant will receive all treatments in a 5-way crossover design.

03

Conditions studied

  • Drug Abuse, Medication
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy adult protocol-defined recreational cannabinoid user
  • Meets protocol-specified criteria for qualification and
  • Able to speak, read and understand English well enough to understand the nature of the study, provide written , and to allow completion of all study assessments
  • Provides written informed consent prior to any protocol-specific procedures, and agrees to abide by all protocol-specified requirements and restrictions

Exclusion criteria

Exclusion Criteria:

  • Dependence on any substance other than nicotine or caffeine beyond protocol-specified limits
  • Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff, 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding), 3) the analysis of results
  • Unwilling, unable, or unlikely to follow protocol-specified restrictions on food, drink, nicotine or physical activities (such as exercise and driving)
  • An employee of the sponsor or research site personnel directly affiliated with this study or their immediate biological or adopted family member defined as a spouse, parent, child or sibling
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 1
Allocation
Not applicable
Intervention model
Single group
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
43 participants (actual)

Study arms

  • Experimental
    All Enrolled Participants

    Each participant receives all treatments (of placebo, dronabinol 10 mg and dronabinol 30 mg) in a 5-way crossover design. At each treatment visit, participants receive a single dose, contained in two syringes of oral solution and three capsules. When dronabinol is in syringes, placebo is in capsules, and when dronabinol is in capsules, placebo is in syringes. When assigned to take placebo only, placebo is in both the syringes and the capsules.

    Drug: Dronabinol 10 mg · Drug: Dronabinol 30 mg · Drug: Placebo

Interventions

  • Dronabinol at a strength equivalent to 10 mg provided in capsules or as an oral solution in syringes.

  • Dronabinol at a strength equivalent to 30 mg provided in capsules or as an oral solution in syringes.

  • DrugPlacebo

    Matching placebo provided in capsules or as an oral solution in syringes.

06

What researchers measure

Primary outcomes

  1. Peak score (Emax) on Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking

    Time frame: within 24 hours post-dose

Secondary outcomes

  1. Peak score (Emax) for Drug Effects, calculated from scores on a VAS scale of 0-100, where 0=not at all and 100=extremely

    Categorical measures = Good drug effects, High, Stoned, Bad effects, Any effects

    Time frame: within 24 hours post-dose

  2. Peak score (Emax) for a shortened Addiction Research Center Inventory (ARCI) scale of 0-49, where 49 is the highest possible score

    Categorical measures = Euphoria, Dysphoria, Sedation, Marijuana

    Time frame: within 24 hours post-dose

  3. Peak score (Emax) for Subjective Drug Value (SDV) in dollars

    Time frame: within 24 hours post-dose

  4. Time-averaged Area under the Effect Curve (TA_AUC) for Drug Effects, calculated from scores on a VAS scale of 0-100, where 0=not at all and 100=extremely

    Categorical measures = Good drug effects, High, Stoned, Bad effects, Any effects

    Time frame: within 24 hours post-dose

  5. Overall Drug Liking (Emax/Emin) calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking

    Time frame: within 24 hours post-dose

  6. Time-averaged Area under the Effect Curve (TA_AUC) for Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking

    Time frame: within 24 hours post-dose

  7. Time-averaged Area under the Effect Curve (TA_AUC) for a shortened Addiction Research Center Inventory (ARCI) scale of 0-49, where 49 is the highest possible score

    Categorical measures = Euphoria, Dysphoria, Sedation, Marijuana

    Time frame: within 24 hours post-dose

  8. Trough Score (Emin) for Drug Liking calculated from a 100-point visual analogue scale (VAS), where 0=strong disliking and 100=strong liking

    Time frame: within 24 hours post-dose

  9. Peak score (Emax) for Take Drug Again, calculated from scores on a VAS scale of 0-100, where 0=definitely not and 100=definitely so

    Time frame: within 24 hours post-dose

  10. Peak score (Emax) for Alertness/Drowsiness, calculated from scores on a VAS scale of 0-100, where 0=very drowsy and 100=very alert

    Time frame: within 24 hours post-dose

  11. Time-averaged Area under the Effect Curve (TA_AUC) for Alertness/Drowsiness, calculated from a 100-point visual analogue scale (VAS), where 0=very drowsy and 100=very alert

    Time frame: within 24 hours post-dose

07

Study locations

1 site
  • INC Research Toronto, Inc.
    Toronto, Ontario M5V 2T3, Canada
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Feb 2014, a primary completion of May 2014 and a completion of May 2014. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 14, 2014
First posted
Mar 24, 2014
Start
Feb 2014
Primary completionActual
May 2014
CompletionActual
May 2014
Last update
May 13, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 13, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02094599
Responsible party
Sponsor
First posted
Mar 24, 2014
Start date
Feb 2014
Primary completion
May 2014
Completion
May 2014
Last update
May 13, 2014

Study contacts

Larry Dillaha, MD
study director · INSYS Therapeutics Inc
Michael McDonnell, MD
principal investigator · INC Research Toronto, Inc.
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Dronabinol

Start the discussion